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Abstract 
Breast cancer is a leading cause of premature 
mortality among United States women. Early 
detection has been shown to reduce breast 
cancer morbidity, mortality and cost of 
treatment. The relative safety of breast cancer 
screening has been viewed in terms of benefits 
and harms. The quality and safety of breast 
cancer screening depends on both technical and 
human factors. Focusing on quality and safety 
considerations, we review two imaging 
modalities recommended for primary breast 
cancer screening: mammography and magnetic 
resonance imaging, and the use of ultrasound 
(US) for supplemental breast cancer screening. 
1Department of Radiology and Imaging Sciences 
and The Huntsman Cancer Hospital, University 
of Utah School of Medicine, Salt Lake City, UT 
Introduction 
Breast cancer is a leading cause of 
premature mortality among U.S. women. 
Early detection has been shown to 
reduce breast cancer morbidity, 
mortality and cost of treatment.1-6 The 
relative safety of breast cancer 
screening has been viewed in terms of 
benefits and harms.7 Varying judgments 
regarding the appropriate balance 
between the benefits and harms of 
screening have resulted in differences 
among recommendation guidelines for 
breast cancer screening (Table 1).8-11 In 
2014, The American Cancer Society 
(ACS) commissioned the Duke 
Evidence Group to conduct a systematic 
review of cancer screening literature for 
updating their breast cancer screening 
guidelines.10, 12  
The quality and safety of breast cancer 
screening depends on both technical 
and human factors. The two primary 
imaging modalities used for primary 
breast cancer screening are 
mammography and magnetic resonance 
imaging (MRI). Nearly all mammograms 
in the U.S. are currently performed with 
digital technology, either as 2D 
mammography or DBT (digital breast 
tomosynthesis, a “pseudo-3D 
mammogram”), and frequently as 
combined 2D/DBT examinations. 
Though ultrasound is used as a 
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supplemental breast cancer screening 
modality in some clinics, it is not 
universally employed or accepted at this 
point in time. We will briefly discuss its 
use as a supplemental screening 
modality to conventional mammography 
screening. However, in this paper, we 
focus primarily on the quality and safety 
considerations for the primary imaging 
modalities used for breast cancer 
screening: x-ray based digital 
mammography (2D or DBT) for average 
risk populations and MRI for high risk 
populations. 
TABLE 1. Breast Cancer Screening Guidelines – Average Risk Women 
 
 








Women at average risk of breast cancer should be offered screening 
mammography starting at age 40 years. If they have not initiated screening 
in their 40s, they should begin screening mammography by no later than 
age 50 years. 
 
The decision about the age to begin mammography screening should be 
made through a shared decision- making process. This discussion should 
include information about the potential benefits and harms. 
 
Women at average risk of breast cancer should have screening 
mammography every one or two years based on an informed, shared 
decision-making process that includes a discussion of the benefits and 
harms of annual and biennial screening and incorporates patient values 
and preferences. 
 
Women at average risk of breast cancer should continue screening 
mammography until at least 75 years. Beyond age 75 years, the decision to 
discontinue screening mammography should be based on a shared decision 
making process informed by the woman's health status and longevity. 
 
American Cancer Society, 2015 
10 
 
Women ages 40 to 44 should have the choice to start annual breast cancer 
screening with mammograms, if they wish to do so. 
 
Women age 45 to 54 should get mammograms every year. Women 55 and 
older can switch to mammograms every 2 years, or can continue yearly 
screening. 
 
Screening should continue as long as a woman is in good health and is 
expected to live 10 more years or longer. 
 
American College of Radiology 
/ Society of Breast Imaging 11 
 
Annual mammographic screening beginning at age 40. 
 
The age to stop should be based on each woman’s health status rather than 
an age-based determination. 
 
Women should be helped to understand the risks of screening; weighing 
benefits and risks should be done by women, not for women. 
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The Mammography Quality 
Standards Act (MQSA) 
The standards for mammography quality 
and safety were largely established by 
the MQSA. In 1992, Congress enacted 
the law with the aim of ensuring quality 
and uniformity through federal regulation 
of mammography and other breast 
procedures involving ionizing radiation 
(i.e., X-rays). By 1994, FDA Interim 
Rules required all mammography 
facilities in the United States to be 
accredited, certified and inspected. The 
MQSA law established mandatory 
testing of equipment by physicists, 
specific training and experience criteria 
for radiologists and technologists 
(baseline training, continuing medical 
education hours, and number of 
mammograms a technologist should 
perform and a radiologist should read 
over 2-year time periods), and 
quantitative evaluation of image quality 
by ratings of phantom and clinical 
images. Throughout the 1990’s, 
emphasis focused on inadequate 
equipment, radiation safety and 
improving the interpretation of 
mammographic images by radiologists. 
Under the MQSA law, FDA-approved 
accrediting bodies review clinical and 
phantom images from every facility once 
every 3 years to monitor compliance 
with quality standards and ensure 
patient safety. 
Over the last 20 years, several 
amendments to the MQSA legislation 
have been made. For example, a 
modification was designed to ensure 
that women with abnormal 
mammograms were not lost to follow-up 
by requiring that mammography centers 
send women a copy of their 
mammogram report in lay language. In 
addition, although not required by the 
MQSA at this point in time, many states 
now require that mammography reports 
also inform women of their breast 
density. Now enacted in over 30 states, 
breast density notification laws vary 
widely but are intended to inform women 
who have undergone mammography 
about the risks posed by their breast 
density and to encourage discussions 
with their primary care providers about 
the need for supplemental screening. 
One very helpful website, created by the 
California Breast Density Information 
Group (CBDIG), includes educational 
materials for women13 and for health 
care providers.14 Most recently, on 
February 15, 2019, Congress passed a 
new federal law mandating that the FDA 
develop breast density reporting 
language that must be included in 
patient letters and healthcare provider 
reports. The exact language and 
effective date are still under 
development as proposed changes to 
the FDA/MQSA requirements. 
Radiation Safety 
An important safety concern regarding 
the equipment used to acquire 
mammograms during the initial 10 years 
of the MQSA was radiation dose.15-17 
Because women undergoing screening 
mammography are healthy (i.e., without 
breast symptoms), the initial MQSA 
regulations included requirements that 
specified a radiation dose limit for each 
of the four breast images acquired for a 
screening mammogram. Per exposure, 
the average x-ray dose is limited to no 
greater than 3 milligray (mGy) to a 
specialized mammography quality 
control phantom that simulates a 
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compressed breast thickness of 4.2 cm 
and a breast composition of 50% 
adipose and 50% glandular tissue. A 
specialized phantom is used to measure 
radiation dose for 2D and DBT 
mammography as well as certain other 
aspects of image quality. Systems 
exceeding the allowed dose may not be 
used for patient imaging. Over time, the 
number of facilities failing to meet dose 
limits or other mammography system 
requirements dramatically declined, in 
part due to the transition from film-based 
to digital mammography.18,19  In the 
current era of mammography 
technology, most systems operate well 
below the allowed dose. In fact, all 
contemporary systems are capable of 
obtaining both a 2D and DBT 
mammogram exposure within the dose 
limits for a single view. 
Mammography Reporting and 
Interpretation Quality 
An early screening mammography 
quality issue was the variability and 
ambiguity of mammography reports.20-25 
In the late 1980’s, an expert panel for 
the American College of Radiology 
studied the lack of standardization and 
uniformity in mammography practice 
reporting and instituted the Breast 
Imaging Reporting and Data System, 
also known as BI-RADS.26 A critical 
component of the system was a data-
driven lexicon of descriptors for specific 
imaging findings predictive of benign 
and malignant disease. Now in its  5th 
edition, the BI-RADS mammography 
practice management system27 includes 
(1) a lexicon of descriptors, (2) a 
recommended reporting structure 
including final assessment categories 
with accompanying management 
recommendations, and (3) a framework 
for data collection and auditing.28 BI-
RADS reporting enables radiologists to 
organize their reports to communicate 
clear and consistent results and specific 
management recommendations to 
referring healthcare providers. A 
summary of the BI-RADS categories, 
management recommendations, and 
likelihood of malignancy is provided in 
Table 2. 
Another interpretation quality concern is 
the variability in radiologists’ 
recommendations for recall for 
additional work-up and/or biopsy after a 
screening mammogram.20,21,23-25,29 
Recognized interventions shown to 
improve radiologists’ mammographic 
interpretations include: fellowship 
training in breast imaging,30 double 
reading and interpreting an adequate 
volume of screening 
mammograms,22,31,32 ensuring that prior 
examinations are available to compare 
with the current exam33 and technical 
tools such as computer-assisted 
detection (CAD) software programs that 
highlight imaging findings to assist 
recognition by the radiologist.32,34,35 It 
should be noted that a recent 
publication found CAD not to be as 
useful for digital mammography.36 The 
number of screening mammograms for 
which a radiologist recommends 
additional diagnostic imaging, commonly 
referred to as the “callback rate” or 
“recall rate”, which do not result in a 
diagnosis of breast cancer (i.e., false 
positive mammography interpretations) 
is considered one of the “harms” of 
mammography. Similarly, 
recommendations for breast biopsy with 
negative, non-cancer pathology (i.e., 
false positive recommendation for 
biopsy) are also considered “harms”. 
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For screening mammography, false 
positive rates tend to be considerably 
higher than false negative rates. Each is 
addressed by performing periodic 
practice audits that track recall rates for 
individual radiologists within breast 
imaging practices, allowing the 
radiologist to focus additional education 
on areas of concern.28 The 
mammography practice audit is a quality 
assurance tool that allows facilities and 
practitioners to recognize areas of 
strength, as well as those areas that 
may need improvement. Acceptable 
interpretive performance criteria, derived 
by Carney et al.37 in 2010, include: (1) 
recall rate 5% - 12%; (2) positive 
predictive value for abnormal 
interpretations on screening 
mammograms 3% - 8%; (3) positive 
predictive value for biopsy 
recommendation 20%-40%; and (4) 
cancer detection rate >2.5 per 1000 
mammograms interpreted. 
 
TABLE 2. BI-RADS Final Assessment Categories 
Category Management Likelihood of cancer 
0 Needs additional imaging and/or 
prior examinations 




1 Negative Routine screening 0% 
 
2 Benign Routine screening 0% 
 
3 Probably benign Short interval follow-up (usually 6 months) >0% but ≤ 2% 
 
4 4a. Low suspicion for malignancy Tissue diagnosis >2% to ≤ 10% 
 
 4b. Moderate suspicion for 
malignancy 
Tissue diagnosis >10% to ≤ 50% 
 
 4c. High suspicion for 
malignancy 
Tissue diagnosis >50% to <95% 
 
5 Highly suggestive of malignancy Tissue diagnosis ≥95% 
 
6 Known biopsy-proven Surgical excision when clinically appropriate N/A 
 
Population-based screening 
mammography data collected by the 
National Cancer Institute (NCI) Breast 
Cancer Surveillance Consortium 
(BCSC)38 has enabled performance 
benchmarking for screening 
mammography.39,40 Regional registries 
within the BCSC link mammography 
data to a state tumor or Surveillance, 
Epidemiology and End Results (SEER) 
registry, and data are pooled at a central 
statistical coordinating center.38 In 2006, 
Rosenberg et al.39 analyzed data from 6 
BSCS registries and found the following 
performance outcomes for U.S. 
mammography practices: (1) recall rate 
= 9.4%; (2) positive predictive value for 
abnormal interpretations on screening 
mammograms = 4.8%; (3) positive 
predictive value for biopsy 
recommendation = 25.0%; and (4) 
positive predictive value for biopsies 
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performed = 32.6%. Cancer detection 
rate (mean cancer detection rate per 
1000 mammograms) was 4.6 and the 
percentage of all cancers diagnosed as 
ductal carcinoma in situ (DCIS) was 
21.6%. A follow-up analysis of BCSC 
data by Lehman et al 40  in 2017 found 
the following: (1) recall rate = 11.6%; (2) 
positive predictive value for abnormal 
interpretations on screening 
mammograms = 4.4%; (3) positive 
predictive value for biopsy 
recommendation = 25.1%; (4) positive 
predictive value for biopsies performed 
= 31.8%; (5) cancer detection rate = 5.1 
per 1000 mammograms; and, (6) 
percentage of all cancers diagnosed as 
ductal carcinoma in situ (DCIS) = 
31.0%. These authors found the 
sensitivity of screening mammography 
increased from 78.7% to 86.9% between 
1996 and 2008, and that more than 92% 
of radiologists achieve the 
recommended cancer detection rate of 
2.5 per 1000 women screened. 
However, they found that 40% of 
radiologists had higher recall rates than 
the recommended upper range of 12% 
by Carney et al.37 Overall, the majority 
of radiologists surpassed performance 
recommendations by the ACR, with the 
exception of recall rate. Excessively 
high recall rates are associated with 
unnecessary additional imaging and/or 
biopsy,29,31,37,40,42  increased costs43 and 
patient anxiety.44-46 Lehman et al. 
recommended that practices establish 
quality improvement programs based on 
their audit data. For example, 
mammograms recalled by radiologists 
with high recall rates were second 
reviewed by radiologists with 
documented high performance for both 
recall and cancer detection rates.40 
Overall, the tradeoff between recall rate 
and high cancer detection rate must be 
balanced to achieve success in breast 
cancer screening.47 
The Most Widespread Quality and 
Patient Safety Concern of Present-
Day Breast Screening Programs 
Currently, the most common quality 
concern and the most frequent cause of 
mammography facility accreditation 
failures is inadequate positioning of the 
breast by the technologist when 
acquiring the images.48 In 2015, the 
American College of Radiology, the 
largest FDA-approved accreditation 
body, found that of all clinical images 
that were deficient on the first attempt at 
accreditation, 92% were deficient in 
positioning and that 79% of all unit 
failures that year were due to 
inadequate positioning. Poor positioning 
poses a significant risk to an individual 
woman because cancers present in any 
portion of the breast not imaged on the 
mammogram cannot be detected. 
Maintaining proper positioning requires 
that the interpreting radiologist 
communicate regularly with the 
technologist to provide feedback on the 
adequacy of positioning and initiate 
corrective actions when problems are 
identified. In 2017, the EQUIP initiative 
(Enhancing Quality Using the Inspection 
Program) was instituted under the 
MQSA.49 The aims of EQUIP are to 
ensure each facility has procedures for 
corrective action when clinical images 
are of poor quality, including 
mechanisms to provide ongoing 
feedback to mammography 
technologists and to document the 
corrective actions taken. To ensure 
compliance with clinical image quality 
standards for accreditation, a sample of 
mammograms performed by each 
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technologist is reviewed regularly by the 
supervising radiologist. During each 
annual inspection, facilities must present 
documentation of their clinical image 
reviews since their last inspection. 
Supplemental Screening with Breast 
MRI for High-Risk Women 
While screening mammography has 
been shown to reduce breast cancer 
mortality by more than 40% in women 
aged 40 years and older, some women 
of higher-than-average risk should begin 
screening at an earlier age and possibly 
using a multimodality approach. In this 
section, the quality and safety concerns 
of breast MRI will be discussed. 
Women undergoing screening who are 
identified with potentially increased risk 
of breast cancer should have further risk 
assessment. Validated assessment 
tools include Gail, BRCAPRO, Tyrer-
Cuzick, or the Claus models. Based on 
the risk assessment, women may 
benefit from genetic counseling, 
enhanced screening such as MRI, more 
frequent clinical breast exams, or risk-
reduction strategies.50-53 
Recommendations for high risk 
screening from the American College of 
Obstetricians and Gynecologists,50,51 the 
American Cancer Society,52 and the 
American College of Radiology/Society 
of Breast Imaging53 are summarized in 
Table 3. 
Compared with the general population, 
women with higher risk are more likely 
to be diagnosed with larger, node-
positive malignancies on screening 
examinations, and also experience 
higher interval cancer rates.53 One of 
the ancillary studies that may be 
performed on these higher-risk women 
is breast MRI. Contrast-enhanced 
breast MRI increases cancer detection 
in higher-risk women and is more 
sensitive than either mammography or 
ultrasound. Breast MRI can significantly 
improve detection of cancer that is 
otherwise clinically, mammographically, 
and sonographically occult. While 
routine screening breast MRI currently is 
not recommended for asymptomatic, 
average-risk women, breast MRI is 
recommended as a high-risk screening 
exam for women with a calculated risk 
of 20% or more of developing breast 
cancer in her lifetime, in addition to 
mammography.50-53 Examples include 
women with genetic predisposition, as 
determined by gene testing or family 
pedigree, and women who received 
chest radiation therapy before age 30. 
For these high-risk women, screening 
breast MRI should be performed 
annually beginning at age 25 to 30. After 
age 30, both MRI and mammography 
are recommended; many women prefer 
to alternate the screening tests so that 
either MRI or mammography is 
performed every 6 months. 
Assuring Patient Safety for Breast 
MRI 
Women should be interviewed and 
screened for possible contraindications 
for MRI. Possible contraindications 
include presence of most cardiac 
pacemakers, ferromagnetic intracranial 
aneurysm clips, certain 
neurostimulators, and cochlear implants. 
In addition, patients suffering from 
anxiety or claustrophobia may require 
sedation or additional assistance. 
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CBE every 6-12 months and annual breast MRI, ages 25-29; for ages> 29, CBE every 6-12 
months, annual mammography and breast MRI (may alternate tests every six months) for 
women who: 
• are estimated to have a lifetime risk of breast cancer of 20% or greater, based on 
risk models that rely largely on family history, but who are either untested or test 
negative for BRCA gene mutations 
• test positive for BRCA1 or BRCA2 mutations 
• have first-degree relatives with these mutations but who are untested are 
generally managed as if they carry these  mutations until their BRCA status is 
known 
• have a personal history of high-risk breast biopsy results, including atypical 
hyperplasia and lobular carcinoma in situ 
 
Women and girls who received thoracic irradiation between age 10 years and 30 years 
have an increased risk of cancer and should be advised to receive the following screening 
regimen:  
• beginning 8–10 years after they received treatment or at age 25 years, whichever 
occurs later: annual mammography, annual breast magnetic resonance imaging 




Women who are at high risk for breast cancer should have an MRI and a mammogram 
every year, typically starting at age 30. This includes women who have a lifetime risk of 
breast cancer of ≥20% or greater, according to risk assessment tools that are based 
mainly on family history, including women who: 
 
• Have a known BRCA1 or BRCA2 gene mutation 
• Have a first-degree relative (parent, brother, sister, or child) with a BRCA1 or 
BRCA2 gene mutation, and have not had genetic testing themselves 
• Had radiation therapy to the chest when they were between the ages of 10 and 30 
years 
• Have Li-Fraumeni syndrome, Cowden syndrome, or Bannayan- Riley-Ruvalcaba 
syndrome, or have first-degree relatives with one of these syndromes 
 
The American Cancer Society recommends against MRI screening for women whose 
lifetime risk of breast cancer is less than 15%. 
American College 
of Radiology / 




Same as ACS for ≥20% risk PLUS: 
 
Breast MRI is recommended for women with personal histories of breast cancer and 
dense tissue, or those diagnosed by age 50. 
 
All women, especially black women and those of Ashkenazi Jewish decent, should be 
evaluated for breast cancer risk no later than age 30 so that the need for supplemental 
screening in those of higher risk can be identified. 
 
Increased parenchymal enhancement on screening breast MRI has been 
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observed during the secretory phase of 
the menstrual cycle. This normal 
enhancement may give rise to false 
positive and false negative MRI scans. It 
is recommended that breast MRI scans 
be performed during the second week of 
the menstrual cycle for patients 
undergoing screening examinations in 
order to reduce the background 
enhancement. 
Gadolinium contrast enhancement is 
required for the evaluation of breast 
parenchyma, as this contrast agent 
increases the conspicuity of diseased 
tissues. Gadolinium-based contrast 
agents (GBCAs) are not administered to 
patients with acute kidney injury and/or 
severe chronic kidney disease because 
of the increased risk of nephrogenic 
systemic fibrosis. In terms of adverse 
reactions, GBCAs are extremely well 
tolerated by most patients, and acute 
adverse reaction events are low ranging 
from 0.07% to 2.4%. Nevertheless, 
appropriate emergency equipment with 
medications should be immediately 
available to treat adverse reactions 
associated with administered 
medications. 
Recently, residual gadolinium deposits 
have been found within the brain tissue 
of patients who received multiple doses 
of GBCAs over their lifetimes, most 
notably in the dentate nuclei and globus 
pallidus.54 The gadolinium deposition in 
the brain may be dose dependent and 
can occur in patients with no clinically 
evident kidney or liver disease. To date, 
however, no adverse health effects have 
been uncovered, but the radiology 
community continues investigations in 
the area to explore the mechanisms of 
gadolinium deposition as well as its 
clinical and biological significance. 
Accreditation and Documentation 
Unlike mammography, breast MRI 
accreditation is voluntary. However, in 
order to achieve Breast Imaging Center 
of Excellence (BICOE – see below) 
status,55 breast MRI accreditation is 
necessary. Through the American 
College of Radiology (ACR), the Breast 
MRI Accreditation Program provides 
facilities performing breast MRI 
procedures with peer review and 
constructive feedback on staff 
qualifications, equipment, quality 
control, quality assurance, MR safety 
policies, and image quality. 
Documentation and reporting of 
screening breast MR examinations are 
standardized in accordance with ACR 
BI-RADS lexicon for Breast MRI, 
including BI-RADS final assessment 
codes and terminology for reporting and 
tracking outcomes.56 Examinations are 
systematically reviewed and evaluated 
as part of the overall quality 
improvement program at the facility. 
Evaluation includes technical adequacy 
of the examination, as well as accuracy 
of interpretation and appropriateness of 
indications for the examinations. Each 
facility should also establish and 
maintain a medical outcome audit 
program to follow up positive 
assessments and to correlate radiology 
and pathology outcomes for 
concordance. 
Pitfalls and Other Considerations 
with Breast MRI 
As with screening mammography, false-
positive results occur with breast MRI. 
These non-malignant abnormalities 
detected on breast MRI may result in 
follow-up examinations or 
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recommendations for biopsy, resulting in 
patient anxiety or post-biopsy 
complication such as hematoma – which 
is more common following MRI-guided 
biopsy than stereotactic or ultrasound-
guided breast biopsies. In addition, 
currently used imaging protocols for 
screening breast MRI are time-
consuming and expensive. There are 
studies evaluating abbreviated (fast) 
MRI protocols, which would make 
contrast-enhanced MRI a more cost-
effective screening tool. Preliminary 
studies have reported these abbreviated 
MRI protocols to have similar 
sensitivities and specificities compared 
to full MRI protocol.57-59  
Supplemental Screening with 
Ultrasound for Women with Dense 
Breast Tissue 
With many states enacting legislation 
requiring that the screening 
mammography report to patients and 
their healthcare providers include 
information on the woman’s breast 
density, many screening centers now 
offer supplemental breast ultrasound 
(US) screening examination to women 
with dense breasts or at elevated risk for 
developing breast cancer. Screening US 
examinations are performed by either a 
technologist or a radiologist using a 
standard hand-held ultrasound probe to 
scan the entirety of both breasts or 
using an automated system to perform 
the examination in a standardized 
fashion. In the majority of cases 
screening US is performed in 
conjunction with screening 2D 
mammography or DBT. The most noted 
U.S. prospective clinical trial evaluating 
this approach was the ACRIN 6666 
Trial.60 In this study, 2,809 women at 
elevated risk for breast cancer, with 
heterogeneous or extreme density 
breast tissue in at least one quadrant 
were evaluated with both 
mammography and screening US, in 
randomized order. 41 breast cancers 
were diagnosed: 8 suspicious on both 
US and mammography, 12 on US 
alone, 12 on mammography alone, and 
9 were interval cancers. The diagnostic 
accuracy for mammography was 7.6 
cancers/1000 screened and increased 
to 11.8/1000 when combined with 
supplemental ultrasound. DCIS were 
only seen by mammography. The false 
positive rate for mammography alone 
was 4.4%, for US alone was 8.1% and 
for combined mammography plus US 
was 10.4%. Thus, if a higher false 
positive rate is acceptable for women 
with dense breasts, combined 
mammography plus US screening will 
diagnose more cancers in this 
population.  
In the same study, when Berg et al. 
compared the value of supplemental US 
vs supplemental breast MRI to 
screening mammography, both US and 
MRI increased the yield of breast 
cancers diagnosed (US: 3.7 
cancers/1000 screened; MRI: 14.7/1000 
screened), but both were associated 
with increases in false-positive findings 
in terms of increased recall rates and 
increased recommendations for biopsies 
that were found not to be cancer.61 
In addition to concerns about high recall 
and false positive biopsy 
recommendation when ultrasound is 
used in conjunction with screening 
mammography, variation in the 
performance and interpretation of the 
exams has been a concern. In two other 
studies that evaluated interobserver 
variation in the interpretation of 
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automated whole breast screening 
ultrasound, agreement between 
radiologists was found to be moderate 
(lesion detection) to good (lesion 
characterization).62,63  
 
Assuring Patient Safety for Screening 
Ultrasound 
Because US does not use ionizing 
radiation or require intravenous contrast, 
it is a safe technology for breast cancer 
screening. However, its high recall and 
false positive biopsy recommendation 
rates are areas of focus for improving its 
performance. When a potential lesion 
identified on a screening exam is 
performed by an automated system, an 
additional “diagnostic” study, using a 
hand-held transducer is performed to 
characterize the lesion, which adds 
complexity to the overall screening 
process. 
Accreditation and Documentation 
Like breast MRI, breast ultrasound 
accreditation is voluntary, but required 
for BICOE certification.55 The ACR 
Ultrasound Accreditation Program 
provides facilities performing breast 
ultrasound and ultrasound-guided breast 
biopsies peer review and constructive 
feedback on staff qualifications, 
equipment, quality control, quality 
assurance, accuracy of needle 
placement and image quality.64 The 
program accredits facilities providing 
services by radiologists, breast 
surgeons and other practitioners 
meeting the program’s qualifications.  
To ensure uniformity in describing 
lesions evaluated by ultrasound, the 
ACR BIRADS Atlas has a section 
devoted to ultrasound image acquisition, 
image quality, transducer frequency, 
labeling and correct lesion 
measurement. Standardized 
terminology for describing lesions and 
wording reports and providing a final 
assessment with management 
recommendations is also provided.65 
The Altas focuses on ultrasound 
characterization of mammographic and 
palpable abnormalities and does not 
address screening ultrasound. Though 
the ACR has developed practice 
parameters for the performance of a 
diagnostic breast ultrasound 
examination, the document does not 
address ultrasound examinations 
performed as supplemental screening 
for breast cancer detection.66  
Breast Imaging Centers of Excellence 
Centralized breast cancer screening 
programs with extensive quality 
assurance activities are currently 
operated by national health care 
systems in several countries outside of 
the U.S. While adapting such programs 
to the diverse and somewhat 
fragmented U.S. health care delivery 
systems may not be fully feasible, 
programs like the NCI BCSC have 
shown the value of and improvements 
realized by quality and safety mandates, 
data registries and performance 
benchmarks. Similarly, interdisciplinary 
breast centers of excellence can 
optimize the broad range of techniques, 
therapies and management practices to 
address breast cancer screening, 
diagnosis and treatment. The ACR 
Breast Imaging Center of Excellence 
(BICOE) accreditation program55 and 
the American College of Surgeons 
National Accreditation Program for 
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Breast Centers (NAPBC)67 are two 
recognized national programs that 
accredit centers of excellence. To 
receive designation as an ACR Breast 
Imaging Center of Excellence, a 
mammography facility must be fully 
accredited by the ACR in 
mammography, stereotactic breast 
biopsy, breast ultrasound, ultrasound-
guided breast biopsy and breast MRI. 
ACR BICOE accreditation is voluntary 
and renewable every three years. 
Summary 
Mammography has been the primary 
breast cancer screening modality for 
more than five decades. The quality and 
safety of screening mammography has 
been improved by requiring specific 
training and continuing experience and 
education for radiologists and 
technologists; standardizing the terms 
and descriptors used in reporting 
findings; providing women with their 
mammography results and follow-up 
recommendations; tracking performance 
and outcomes through practice audits; 
ensuring compliance with accreditation 
requirements; and performing periodic 
facility inspections. The future of breast 
cancer screening will entail tools 
providing a more personalized 
understanding of cancer risk to better 
guide the type and frequency of 
screening test performed for an 
individual woman. Programs and 
practices must be cognizant that the 
majority of women undergoing 
screening will never develop breast 
cancer and that patient safety, quality 
assurance and benchmarks for 
performance outcomes remain vital to 
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